With the approval of a number of ADC drugs around the world since 2019, conjugated drugs have developed into one of the hottest tracks in the pharmaceutical industry. Not only traditional ADCRead More…
New structures to resolve the instability of Maleimide joint
An ADC consists of an antibody and toxin bridged by a linker that affects the coupling stability to some extent and has an important influence on ADC efficacy. The premature release ofRead More…
Ushering in a “Raging” Era—Fiercely Competitive Phase III ADCs (part I)
An antibody-drug conjugate (ADC) is composed of an antibody, a chemical linker, and a small molecular payload, and takes advantage of the specific targeting binding ability of antibody to transport cytotoxic payloadRead More…
Analytical methods of average drug to antibody ratio (DAR) of antibody-drug conjugates
Antibody-drug conjugate (ADC) is a new type of biological targeting drug for the cancer treatment, which perfectly combines the high specificity of antibody and the strong lethal power of cytotoxin. With theRead More…
Unprecedented!—FDA accelerates the approval of CD19-ADC
Recently, FDA has accelerated the approval of ADC Therapeutics’ targeted CD19-ADC drug Loncastuximab tesirine for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). It is worth mentioning that,Read More…
How To Design Elite ADCs?
After more than 20 years of development, ADC drug is becoming the main force in cancer treatment, which, compared with traditional chemotherapy, has a wider application scope. However, minimizing ADCs’ non-target toxicityRead More…
Immunogenicity, a Headache of ADC Developers
Protein drugs have the potential to induce immunogenicity, whose consequences may affect the efficacy or even be life-threatening. New models of biotherapy, such as antibody-conjugated (ADC) drugs, fusion proteins, and polyethylene glycolization,Read More…
Fast-Tracking ADC Drugs Manufacturing and Production Technology
When we get an ideal candidate for ADC, the next step is to consider how to scale it up. This step is important because it is directly related to the post-market marketRead More…
Overview: Mechanism of Action of ADC
Specific Binding ADC drugs specifically bind to antigenic epitopes of cancer cells through their “guiding” antibodies, and enter into cancer cells through antigen-mediated endocytosis, then release the “warheads” – highly active cytotoxicRead More…
Comprehensively Review Targets for ADC
At present, ADC drugs are mainly used in the field of tumors, so antigenic targets are required to be highly expressed in tumor cells but with low or no expression in normalRead More…